Pfizer PROGRES
Research type
Research Study
Full title
Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi-country, non-interventional prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care
IRAS ID
301829
Contact name
Mehul Tulsidas Dattani
Contact email
Sponsor organisation
Pfizer Inc.
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
10 years, 2 months, 1 days
Research summary
The Progres study will collect information about participants who are receiving a growth hormone treatment as part of their regular care. The study involves recording information about the participant’s medical treatment and health at routine clinic visits, and completion of two questionnaires. No extra clinic visits are necessary.
This non-interventional study is designated as a Post-Authorization Safety Study (PASS) and is sponsored by Pfizer and will be conducted in approximately 512 participating sites in over 20 countries around the world. In the UK, the study is planned to enrol 800 patients from around 40 sites. Male and female patients of any age meeting the eligibility criteria can be enrolled into the study. Recruitment will continue until October 2029 and the study will end in October 2030.
REC name
South Central - Hampshire B Research Ethics Committee
REC reference
21/SC/0354
Date of REC Opinion
14 Dec 2021
REC opinion
Further Information Favourable Opinion